# Diagnostic Performance of Serological Assays in the Detection of SARS-CoV-2: A Review
## 3 Results
### Results of Individual Studies
\begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Study** & **Total Sample** & **IgM/IgG-Positive Patients** & **IgM/IgG-Negative Patients** & **IgM-Positive** & **IgG-Positive** \\ \hline  & 50 patients at their first & & & \\  & access to emergency & & & \\  & department, later tested & & 1/12 negative patients (8.3\%) & & \\  & for COVID-19 by RT-CR: & & & \\  & 12 negative 38 positive & & & \\  & 22 blood samples & & & \\  & 24 & & & \\ \hline  & & & & \\ \end{tabular}
\end{table} 
Table 4: Anti-SARS-CoV-2 IgM and IgG rates in patients with suspected infection/fever and respiratory syndrome (positivity to COVID-19 not confirmed by RT-PCR). \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Study** & **Total Sample** & **IgM/IgG-Positive Patients** & **IgM/IgG-Negative Patients** & **IgM-Positive** & **IgG-Positive** \\ \hline
[32] & 30 & 19/30 (63.3\%) 5/30 (16.7\%) & 5/30 (16.7\%) & 1/30 (3.3\%); IgM-positive & \\  & weakly positive & & and IgG-negative & \\
[33] & 64 & 41/64 (64.1\%) & & 3/64 (4.7\%) & 5/64 (7.8\%) \\
[34] & 27 & & 3/27 (11.1\%) & 13/27 (48\%) & 24/27 (88.9\%) \\
6 with symptoms 8 & & & & 4/6 (66.6\%) & 6/6 (100\%) \\
35 without symptoms/mild & & & & 0/8 (70) & 3/8 (37.5\%) \\ symptoms & & & & & \\  & 397 & 256/397 (64.4\%) & & 72/397 (18\%) & 24/397 (6.0\%) \\
[37] & 86 blood samples & & & 48/86 (55.8\%) & 4/786 (54.7\%) \\
[38] & 66 & & & 51/66 (77.2\%) & 55/66 (83.3\%) \\
[39] & 173 & & & 143/173 (82.7\%) & 112/173 (64.7\%) \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Anti-SARS-CoV-2 IgM and IgG rates in the COVID-19-positive population sample. \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Study** & **Total Sample** & **IgM/IgG-Positive Patients** & **IgM/IgG-Negative Patients** & **IgM-Positive** & **IgG-Positive** \\ \hline
[32] & 30 & 19/30 (63.3\%) 5/30 (16.7\%) & 5/30 (16.7\%) & 1/30 (3.3\%); IgM-positive & \\  & weakly positive & & and IgG-negative & \\
[33] & 64 & 41/64 (64.1\%) & & 3/64 (4.7\%) & 5/64 (7.8\%) \\
[34] & 27 & & 3/27 (11.1\%) & 13/27 (48\%) & 24/27 (88.9\%) \\
[35] & 6 with symptoms 8 & & & 4/6 (66.6\%) & 6/6 (100\%) \\
[35] & without symptoms/mild & & & 0/8 (70) & 3/8 (37.5\%) \\ symptoms & & & & & \\
[36] & 397 & 256/397 (64.4\%) & & 72/397 (18\%) & 24/397 (6.0\%) \\
[37] & 86 blood samples & & & 48/86 (55.8\%) & 4/786 (54.7\%) \\
[38] & 66 & & & 51/66 (77.2\%) & 55/66 (83.3\%) \\
[39] & 173 & & & 143/173 (82.7\%) & 112/173 (64.7\%) \\ \hline \hline \end{tabular}
\end{table} 
Table 4: Anti-SARS-CoV-2 IgM and IgG rates in patients with suspected infection/fever and respiratory syndrome (positivity to COVID-19 not confirmed by RT-PCR). \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**P** & **Total Sample** & **IgM/IgG-Positive Patients** & **IgM/IgG-Negative Patients** & **IgM-Positive** & **IgG-Positive** \\ \hline
[32] & 30 & 30 (100\%) & & \\
[34] & 33 & & 0 (0\%) & 3 (9.1\%) \\
[35] & 28 & & 28 (100\%) & & \\
[36] & 128 & 1/128 (0.7\%) & & 10/128 (7.8\%) & 1/128 (0.7\%) \\
[38] & 60 & & & 0/60 (0\%) & 3/  
The gold immunomodhtography assay supplied by Innovita Co., LTd, China (CFDA approved) tested by [PERSON] et al. [40] highlighted that among the coronavirus-2-positive group (21 persons) all the symptomatic patients (17 subjects) were recorded to be seropositive during the follow-up period. [PERSON] et al. [41] developed an in-house anti-SARS-CoV IgG/IgG/IgM ELISA kit (using a cross-reactive nucleocapsid protein from another SARS-related virus, Rp3, which is 92% identical to SARS-CoV-2 nucleocapsid protein), employing it to investigate the antibody response in 16 positive participants: this study demonstrated that IgM and IgG titers were low or undetectable on the day of first sampling (day 0), and that, on day 5, an increase in viral antibodies could be observed in nearly all patients: IgM and IgG positive rate increased from 50% (8/16) to 81% (13/16) and from 81% (13/16) to 100% (16/16). The ELISA kit supplied by Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., used by [PERSON] et al.